A Phase I Study of Bevacizumab in Combination With SU11248.
Phase of Trial: Phase I
Latest Information Update: 13 Dec 2013
At a glance
- Drugs Bevacizumab (Primary) ; Sunitinib (Primary)
- Indications Adrenocortical carcinoma; Malignant melanoma; Solid tumours
- Focus Adverse reactions
- 01 Jun 2012 Actual patient number 60 added as reported by ClinicalTrials.gov.
- 01 Jun 2012 Planned end date changed from 1 Oct 2012 to 1 Sep 2012 as reported by ClinicalTrials.gov.
- 01 Jun 2012 Status changed from suspended to active, no longer recruiting as reported by ClinicalTrials.gov.